- Home
- CLGN vs FGEN Comparison
CLGN vs FGEN Comparison
Compare CLGN & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- FGEN
- Stock Information
- Founded
- CLGN 2004
- FGEN 1993
- Country
- CLGN Israel
- FGEN United States
- Employees
- CLGN N/A
- FGEN N/A
- Industry
- CLGN Industrial Specialties
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CLGN Health Care
- FGEN Health Care
- Exchange
- CLGN Nasdaq
- FGEN Nasdaq
- Market Cap
- CLGN 37.4M
- FGEN 33.5M
- IPO Year
- CLGN N/A
- FGEN 2014
- Fundamental
- Price
- CLGN $2.58
- FGEN $0.32
- Analyst Decision
- CLGN Strong Buy
- FGEN Strong Buy
- Analyst Count
- CLGN 2
- FGEN 1
- Target Price
- CLGN $12.50
- FGEN $10.00
- AVG Volume (30 Days)
- CLGN 12.3K
- FGEN 1.6M
- Earning Date
- CLGN 03-26-2025
- FGEN 03-17-2025
- Dividend Yield
- CLGN N/A
- FGEN N/A
- EPS Growth
- CLGN N/A
- FGEN N/A
- EPS
- CLGN N/A
- FGEN N/A
- Revenue
- CLGN $515,000.00
- FGEN $29,621,000.00
- Revenue This Year
- CLGN $2,474.76
- FGEN $472.13
- Revenue Next Year
- CLGN $52.63
- FGEN $7.13
- P/E Ratio
- CLGN N/A
- FGEN N/A
- Revenue Growth
- CLGN N/A
- FGEN N/A
- 52 Week Low
- CLGN $2.54
- FGEN $0.18
- 52 Week High
- CLGN $6.75
- FGEN $2.40
- Technical
- Relative Strength Index (RSI)
- CLGN 26.97
- FGEN 38.86
- Support Level
- CLGN $2.54
- FGEN $0.30
- Resistance Level
- CLGN $3.70
- FGEN $0.38
- Average True Range (ATR)
- CLGN 0.26
- FGEN 0.05
- MACD
- CLGN -0.04
- FGEN -0.00
- Stochastic Oscillator
- CLGN 3.45
- FGEN 16.30
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.